Levocetirizine Dihydrochloride
For adults and children from 2 years of age
The active substance of Xyzal is levocetirizine dihydrochloride.
Xyzal is an antiallergic medicine.
Xyzal is used to treat symptoms associated with:
Before taking Xyzal, discuss it with your doctor or pharmacist.
If you may have difficulty emptying your bladder (in conditions such as spinal cord injury or prostate enlargement), consult your doctor.
Xyzal may increase the risk of seizures, so consult your doctor if you have a history of seizures or are at risk of seizures.
If you are scheduled to undergo allergy testing, ask your doctor if you should stop taking Xyzal a few days before the test. Xyzal may affect the results of allergy tests.
Xyzal should not be given to infants and young children under 2 years of age.
Tell your doctor or pharmacist about all medicines you are taking, have recently taken, or might take.
Be cautious when taking Xyzal with alcohol or other substances that affect brain function.
In sensitive patients, taking Xyzal with alcohol or other substances that affect brain function may cause additional drowsiness and impaired reaction time.
Xyzal can be taken with or without food.
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Some patients taking Xyzal may experience drowsiness, fatigue, and exhaustion.
Be cautious when driving or operating machinery until you know how Xyzal affects you. However, special tests conducted with healthy volunteers after taking levocetirizine at the recommended dose did not show an effect on attention, reaction time, or driving ability.
Always take this medicine exactly as your doctor or pharmacist has told you.
If you are not sure, ask your doctor or pharmacist.
The recommended dose is:
Adults and adolescents over 12 years: 10 ml of solution once daily.
Kidney and liver function disorders
In patients with kidney function disorders, the dose may need to be reduced depending on the severity of the kidney disease; in children, the dose should also be adjusted according to body weight; the dose will be determined by your doctor.
Xyzal should not be taken by patients with severe kidney disease requiring dialysis.
Patients with liver function disorders only should take the usual recommended dose of Xyzal.
In patients with both liver and kidney function disorders, a lower dose may be necessary depending on the severity of the kidney disease; in children, the dose should also be adjusted according to body weight; the dose will be determined by your doctor.
Elderly patients (65 years and over)
No dose adjustment is necessary in elderly patients with normal kidney function.
Children from 6 to 12 years: 10 ml of solution once daily.
Children from 2 to 6 years: 2.5 ml of solution twice daily.
Xyzal should not be given to infants and young children under 2 years of age.
This medicine is for oral use only.
A measuring syringe is provided with the pack. The solution can be taken undiluted or diluted in a glass of water.
Xyzal can be taken with or without food.
How to use the measuring syringe
Place the syringe in the bottle and pull the plunger to the mark on the syringe that corresponds to the dose in milliliters (ml) prescribed by your doctor. For children under 6 years, the daily dose of 5 ml given in two divided doses should be measured by taking 2.5 ml of solution twice daily (the dose should be measured accurately using the syringe with the scale).
Remove the syringe from the bottle and empty its contents onto a spoon or into a glass of water by pressing the plunger. The medicinal product should be taken orally immediately after dilution.
After each use, rinse the syringe with water.
The duration of treatment depends on the type, duration, and severity of the disease symptoms and is determined by your doctor.
In adults, if a higher dose of Xyzal than recommended is taken, drowsiness may occur. In children, initial excitement and restlessness, especially motor restlessness, may occur, followed by drowsiness.
If you suspect that you have taken a higher dose of Xyzal than recommended, consult your doctor, who will decide what actions should be taken.
If you miss a dose of Xyzal or take a lower dose than recommended by your doctor, do not take a double dose to make up for the missed dose. Take the next dose at the usual time.
Stopping treatment with Xyzal should not cause any harmful effects. However, in rare cases, itching (intense itching) may occur after stopping Xyzal treatment, even if these symptoms did not occur before starting treatment. These symptoms may resolve on their own.
In some cases, these symptoms may be intense and it may be necessary to resume treatment. These symptoms should resolve after resuming treatment.
If you have any further questions about taking this medicine, ask your doctor or pharmacist.
Like all medicines, Xyzal can cause side effects, although not everybody gets them.
Common: may affect up to 1 in 10 people
Dry mouth, headache, fatigue, and drowsiness
Uncommon: may affect up to 1 in 100 people
Exhaustion and abdominal pain
Frequency not known: cannot be estimated from the available data
Other side effects have also been reported, such as: palpitations, increased heart rate, seizures, tingling, dizziness, fainting, tremors, taste disturbances (altered taste perception), feeling of spinning or swaying, vision disturbances, blurred vision, rotational eye movements (uncontrolled circular eye movement), painful or difficult urination, inability to fully empty the bladder, swelling, itching, rash, urticaria (swelling, redness, and itching of the skin), skin eruptions, shortness of breath, weight gain, muscle pain, joint pain, excitement and aggressive behavior, hallucinations, depression, insomnia, recurring suicidal thoughts or interest in suicide, nightmares, hepatitis, abnormal liver function, vomiting, increased appetite, nausea, and diarrhea. Itching (intense itching) after stopping Xyzal treatment.
If you notice the first symptoms of an allergic reaction, stop taking Xyzal and tell your doctor. Allergic reaction symptoms may include: swelling of the lips, tongue, face, and (or) throat, difficulty breathing or swallowing (chest tightness or wheezing), urticaria, sudden drop in blood pressure leading to fainting or shock, which can be life-threatening.
If you experience any side effects, including those not listed in this leaflet, tell your doctor or pharmacist. Side effects can be reported directly to the Department of Drug Monitoring, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help to gather more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the label and carton after "EXP". The expiry date refers to the last day of that month.
There are no special storage precautions for this medicine.
Do not use after 3 months from the date of first opening.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
The oral solution is a clear and colorless solution in a glass bottle with a white polypropylene child-resistant closure. The bottle with the solution is placed in a cardboard box containing a measuring syringe.
Pack sizes: 200 ml.
Marketing authorization holder
VEDIM Sp. z o.o.
ul. Kruczkowskiego 8
00-380 Warsaw
Tel. +48 22 696 99 20
Manufacturer:
Aesica Pharmaceuticals S.r.l., Via Praglia 15, I-10044 Pianezza (TO), Italy
Importer:
UCB Pharma Limited, 208 Bath Road, Slough, Berkshire, SL1 3WE, United Kingdom
ExtractumPharma Zrt., H-6413 Kunfehértó, IV. körzet 6, Hungary
PHOENIX Pharma Polska Sp z o.o., ul. Rajdowa 9, Konotopa, 05-850 Ożarów Mazowiecki
United Drug Distributors Ireland Limited, United Drug House, Magna Drive,
Magna Business Park, Citywest Road, Dublin 24, Ireland
UCB Pharma B.V., Hoge Mosten 2 A1, 4822 NH, Breda, Netherlands
UCB Pharma AS, Haakon VIIs gate 6, NO-0161 Oslo, Norway
UCB Nordic A/S, Edvard Thomsens Vej 14, DK-2300 København S, Denmark
UCB Pharma SA, Chemin Du Foriest 1, Braine-l’alleud, 1420, Belgium
Belgium: Xyzall
Cyprus: Xyzal
Czech Republic: Xyzal
Denmark: Xyzal
Estonia: Xyzal
Finland: Xyzal
France: Xyzall
Germany: Levocetirizin Saft
Greece: Xozal
Hungary: XYZAL 0.5 mg/ml oral solution
Ireland: Xyzal
Italy: Xyzal
Latvia: Xyzal
Lithuania: Xyzal
Luxembourg: Xyzall
Malta: Xyzal
Netherlands: Xyzal
Norway: Xyzal
Poland: Xyzal
Portugal: Xyzal
Slovakia: Xyzal 0.5 mg/ml oral solution
Slovenia: Xyzal
Spain: Xazal
United Kingdom: Xyzal
Date of last revision of the leaflet:December 2023
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.